Navigation Links
Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
Date:10/29/2007

DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that two posters describing significant preclinical studies performed by Access collaborators at two prominent institutes in France, were presented last week at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications One poster provides results of additional studies of the mechanism of ProLindac's anticancer activity, while the second poster demonstrates the potential benefits for cancer therapy of combining ProLindac with other anticancer agents.

"These studies, which are a continuation of work presented at the AACR annual meeting earlier this year, provide further support to our belief that ProLindac has the potential to become an important tool in the fight against cancer" stated David P. Nowotnik, Access' Senior Vice President Research and Development. "One poster shows that the cytotoxicity of ProLindac in a panel of cancer cell lines is greater than that found for either oxaliplatin or cisplatin, while the second poster demonstrates that combinations of ProLindac with certain other anticancer compounds produces cytotoxic effects which are greater than is produced by use of the drugs individually."

In addition, the studies reaffirmed that ProLindac becomes more effective in the lowered pH environment of many tumors by showing that the formation of cancer-killing platinum-DNA adducts increases in tumor cells which are exposed to lower pH conditions. Exposure to ProLindac also resulted in tumor cell cycle arrest at a phase of the cycle where the tumor cell is more susceptible to damage. These effects can lead to programmed death (apoptosis) of the tumor cell. A synergistic effect of ProLind
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...W YORK, Nov. 20 Clinical data from...e 35th Annual Veith Symposium shows DVT,treatment...om Bacchus,Vascular, Inc. (Santa Clara, CA) succe... in about 20 minutes. , This technique, cal...ores,blood flow more quickly and safely than curr...
(Date:11/19/2008)...N FRANCISCO, Nov. 19 Posit Science...idence at the Society for Neuroscience,Annual Con...t cognitive,training may benefit Baby Boomers. T...ess Program (TM) uses adaptive exercises that targ...are designed to drive generalized,improvements in...
(Date:11/19/2008).... Jude scientists report basic findings on critica...g how to better treat an array of disorders , ...e/ -- Scientists at St. Jude Children,s Research ...of one of the body,s enzyme workhorses called calp...evers, calpains function in many cellular processe...
(Date:11/19/2008)...riggers $5 Million Payment from Roche- , , ...Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) tod...oal for its Phase 2 trial of R3487/MEM 3454, its l...ve impairment associated with schizophrenia (CIAS)...Phase 2 trial, triggering a $5.0 million payment f...
Breaking Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3MedCath Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 7180 1CEVA Group Plc Reports Quarter 3 2007 Results 7176 1CEVA Group Plc Reports Quarter 3 2007 Results 7176 2CEVA Group Plc Reports Quarter 3 2007 Results 7176 3CEVA Group Plc Reports Quarter 3 2007 Results 7176 4Finding Ways for Seniors to Stay Safe Healthy and Home 7172 1Finding Ways for Seniors to Stay Safe Healthy and Home 7172 2Finding Ways for Seniors to Stay Safe Healthy and Home 7172 3First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 1993 1First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 1993 2First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 1993 3
...007 - Xanthus,Pharmaceuticals, Inc today presented...clinical and pathological signs of chronic,disease...esentation,was made by Stephen J. Karlik, Ph.D., P... of Western Ontario, London, Ontario,together wit...the,59th American Academy of Neurology Meeting in ...
...nical (IND) In- Vitro,Studies for Promising Alzhei...) -- Samaritan,Pharmaceuticals Inc. (AMEX:LIV), a ...nce positive results were attained with its,late-s...l (SP-233),with well recognized in-vitro models. ...ect predictors,of clinical responses, laboratory a...
Other Medicine Technology:Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 3Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 2Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 3
(Date:11/21/2008)...nd schools need to work together to stop abusive b... (HealthDay News) -- Behavior that was once dismis...ying. , And as mounting research shows the nega...tal-health professionals, schools, parents and eve...ombat this threatening behavior. , "Bullying s...
(Date:11/21/2008)...1, 2008)The University of Texas Health Science Cen... Excellence in Aging Studies (TEXAS), to promote g...gious $2 million award from the Donald W. Reynolds... "This will allow us to teach geriatric medicine p... student to practicing physicians. With the reach ...
(Date:11/21/2008)...Nov. 21 The Providence S...ced that Craig A. Norris, the Company,s,Chief Ope...s Board of,Directors. Mr. Norris, appointment fi...n of Steven I. Geringer and returns the board to s...mittee of the Board. , Mr. Norris, age 41, ...
(Date:11/21/2008)...anzel proved effective against Lennox-Gastaut synd...) -- A new drug called Banzel (rufinamide) has bee...re form of epilepsy called Lennox-Gastaut syndrome...Friday. , The approval was based on results of ... ages 4 to 30. Compared to patients who took a pla...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...has been tons of information circulating around do...ign has asked donor-conceived parents to speak to ...ities were flooded with inquiries in this regard. ...lls and emails from parents of donor-conceived chi...
...bad-based Dishman Pharmaceuticals and Chemicals Lt...rvices business of US-based Solutia Inc for 74.5 m...ement for purchasing 100 per cent stake in CarboGe... pharmaceutical services division, Dishman said in...
...ng a decrease in the child mortality rate from 86 ...lans to bring it down further by earmarking Rs 2.6...ildren. // The benefits reaching women and childr... to all and the government will spend Rs 2.63 cror...
...sing serious concern over growing problems due to ...Social Justice and Empowerment Meira Kumar today s...tems in the region to check it. There is a need to...ng and reporting systems for all seven-sister stat...
Other Medicine News:
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: